TuHURA Biosciences Inc.
HURA | NASDAQ
$2.13
-$0.05 (-2.29%)
Sep 22, 2026, 2:42 PM ET · Market open
Company Profile
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
Key Executives
| Name | Position |
|---|---|
| James A. Bianco | President, Chief Executive Officer & Director |
| Dan Dearborn | Executive Vice President of Finance & Chief Financial Officer |
| Amanda Garofalo | Senior Vice President of Clinical Operations |
| Michael Krsulich | Head of Quality Assurance |
| Michael Lawman | Co-Founder |
| Patricia Lawman | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 04, 2026 | 8-K | Current Report |
| Aug 28, 2026 | SC 13D/A | [Amend] Filing |
| Aug 21, 2026 | 8-K | Current Report |
| Aug 19, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 13, 2026 | 8-K | Current Report |
| Jul 29, 2026 | 8-K | Current Report |
| Jul 09, 2026 | ARS | Filing |
| Jul 09, 2026 | DEFA14A | Filing |
TuHURA Biosciences Inc.
| Country | United States |
| IPO Date | Feb 21, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | James A. Bianco |
Contact Details
10500 University Center Drive Tampa,
Florida 33612 United States
Stock Details
| Ticker Symbol | HURA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001498382 |
| CUSIP Number | 898920103 |
| ISIN Number | US8989201038 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove HURA